Lightlake Therapeutics Inc. (LLTP) to Develop Opioid Drug Treatment in Collaboration With the National Institute on Drug Abuse (NIDA)
4/24/2013 11:32:09 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
3/27/2013 11:15:20 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Appoints Board Member as New Chief Financial Officer
11/30/2012 8:29:28 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Appoints Dr. David Kessler as Strategic Advisor
9/24/2012 10:37:00 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
8/8/2012 10:48:47 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment
5/3/2012 7:19:35 AM
More...
|
Lightlake Therapeutics Inc. Appoints New Board Member
4/17/2012 10:39:03 AM
More...
|
Lightlake Therapeutics Inc. Finishing Patient Testing in Phase II Trial of Patented Binge Eating Disorder Treatment
3/20/2012 9:08:11 AM
More...
|
Lightlake Therapeutics Inc. Comments on Unusual Trading Activity
2/1/2012 9:05:31 AM
More...
|
Lightlake Therapeutics Inc. to Discuss with King's College London’s Institute of Psychiatry on the Development of a New Opiate Overdose Treatment
1/4/2012 6:35:54 AM
More...
|
|